Table 3.
KEGG enrichment results of potential AD drug target genes
| KEGG ID | KEGG pathway | Class | Nominal P‐value | Adjusted P‐value | Enriched genes |
|---|---|---|---|---|---|
| Cutoff P‐value = 0.01 | |||||
| hsa05330 | Allograft rejection | Immune diseaseD | 3.87 × 10− 5 | 2.13 × 10− 3 | HLA‐B, IL−10, CD86 |
| hsa05320 | Autoimmune thyroid disease | Immune diseaseD | 1.06 × 10− 4 | 2.91 × 10− 3 | HLA‐B, IL−10, CD86 |
| Cutoff P‐value = 0.05 | |||||
| hsa05322 | Systemic lupus erythematosus | Immune diseaseD | 1.66 × 10− 3 | 2.93 × 10− 2 | C1QB, IL−10, CD86 |
| hsa05332 | Graft‐versus‐host disease | Immune diseaseD | 2.42 × 10− 3 | 2.93 × 10− 2 | HLA‐B, CD86 |
| hsa04940 | Type I diabetes mellitus | Endocrine and metabolic diseaseD | 2.66 × 10− 3 | 2.93 × 10− 2 | HLA‐B, CD86 |
| hsa04672 | Intestinal immune network for IgA production | Immune systemO | 3.45 × 10− 3 | 3.16 × 10− 2 | HLA‐B, CD86 |
The capital letters beside the class name represent KEGG categories. Among them, D means human disease; O means organismal systems. The adjusted P‐values are obtained through multiple hypothesis testing to correct the nominal P‐values.